Sign up USA
Proactive Investors - Run By Investors For Investors

PreveCeutical Medical Inc upgrades to OTCQB to expand US shareholder base

The index is for early-stage and developing United States and international companies, it said
PreveCeutical Medical Inc upgrades to OTCQB to expand US shareholder base
“We are extremely pleased to be able to upgrade to quote on the OTCQB," the firm said.

Health sciences group PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) said shares began trading on the OTCQB Venture  Marketplace in the US on September 15.

The index is for early-stage and developing United States and international companies.

“We are extremely pleased to be able to upgrade to quote on the OTCQB.

"This listing will enable us to expand our US shareholder base as well as offer the company’s existing US shareholders a more transparent and efficient platform to obtain quotes and trade PreveCeutical securities," said PreveCeutical’s chairman and chief executive Stephen Van Deventer.

The group is developing innovative preventive therapies using organic and nature identical products and currently has five research and development programs.

These are dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

The group also sells CELLB9, an immune system booster.

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use